News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Peptimmune, Inc. Files Under Chapter 7



3/23/2011 8:16:06 AM

Boston Business Journal -- Peptimune, Inc, a privately held biotechnology company in Cambrige, Mass., has filed under Chapter 7 of the bankruptcy code.

The filing came after the company failed to raise a proposed $35 million round of venture capital funding, an executive said. The company had shrunk to five employees from more than 50 last year as resources dwindled.

According to a filing in U.S. Bankruptcy Court for Boston, Peptimmune had $2.01 million in assets, mostly in the form of intellectual property. But Peptimmune had business debts totaling $2.17 million. The company had just $5,963.18 in cash on hand in two bank accounts.

Chapter 7 usually leads to liquidation.

Peptimmune was working on a generic version of the multiple sclerosis drug Copaxone, which is marketed by Israeli drug maker Teva Pharmaceuticals (Nasdaq: TEVA). Peptimmune’s latest trial on the drug candidate had yielded positive results. This asset will revert to a trustee and will likely be bought by another biotech or pharmaceutical company.

The company is being represented by law firm Ropes and Gray in the bankruptcy proceedings.




comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES